Optimization (Central Composite Design) and Validation of HPLC Method for Investigation of Emtricitabine Loaded Poly(lactic-co-glycolic acid) Nanoparticles: In Vitro Drug Release and In Vivo Pharmacokinetic Studies

Table 2

Experimental conditions according to the central composite design and observed response values.

Exp. no.	Run order	𝐴	𝐵	𝑌1	𝑌2	𝑌3
1	8	−1.00	−1.00	9.21	2.52	1.6
2	3	1.00	−1.00	7.64	4.74	1.4
3	4	−1.00	1.00	8.57	3.11	1.6
4	11	1.00	1.00	10.41	4.69	1.8
5	10	−1.00	0.00	5.37	7.81	1.2
6	12	1.00	0.00	12.32	5.62	1.1
7	9	0.00	−1.00	6.35	4.59	1.5
8	7	0.00	1.00	5.61	8.25	1.1
9	2	0.00	0.00	4.76	7.64	1.1
10	1	0.00	0.00	4.79	8.01	1.2
11	5	0.00	0.00	4.77	7.78	1.0
12	6	0.00	0.00	4.81	8.11	1.1
13	13	0.00	0.00	4.78	7.85	1.1

𝐴: methanol concentration (%); 𝐵: mobile phase pH.
𝑌₁: retention times; 𝑌₂: peak resolution; 𝑌₃: peak asymmetry.